| Rx0000101 |
Par Pharmaceutical |
09/30/2020 |
42023011925 |
Tigan®, Trimethobenzamide HCl Inj 100 MG/ML, 2 ML, Unit-Dose, Vial Qty 25 |
07/15/2020 |
95.40 |
1059.06 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/21/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
09/30/2020 |
42023011801 |
Tigan®, Trimethobenzamide HCl Inj 100 MG/ML, 20 ML, Vial |
07/15/2020 |
32.71 |
363.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug. |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 10/21/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2020 |
42023016425 |
Vasostrict®, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 1 mL x 25 VL |
02/14/2020 |
444.25 |
4939.00 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000101 |
Par Pharmaceutical |
03/31/2020 |
42023019001 |
Vasostrict®, Vasopressin IV Soln 20 Unit/ML (For IV Infusion), 10 mL |
02/14/2020 |
177.70 |
1975.60 |
01/30/2035 |
Single Source Drug |
None |
1 |
None |
1 |
The price increase was not necessitated by a change or improvement in the drug |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The information contained in this report is subject to the following limitations and assumptions. (1) Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Par believes is otherwise in the public domain or publicly available. (2) The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of 4/22/2020. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date. If the Orange Book database does not contain any unexpired patents for this product, Par has left the “Patent Expiration Date” field for this product blank. (3) Par did not acquire this product from another manufacturer within the previous five years (i.e. 60 months). As a result, Par has left columns N-U blank because they are not applicable to this product. |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224031060 |
Zohydro ER Oral Capsule 10 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
44.67 |
600.00 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
555.33 |
514.19 |
2014 |
368.40 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376031060 Effective date 03-11-2015 WAC 368.40
NDC 43376031060 Effective date 01-08-2016 WAC 404.87 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224031560 |
Zohydro ER Oral Capsule 15 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
47.49 |
640.80 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, Inc. |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
593.31 |
549.36 |
2014 |
393.60 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376031560 Effective Date 03-11-2015 WAC 393.60
NDC 43376031560 Effective Date 01-08-2016 WAC 432.57 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224033060 |
Zohydro ER Oral Capsule 30 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
50.29 |
681.60 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, LLC |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
631.31 |
584.54 |
2014 |
418.40 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376033060 Effective Date 03-11-2015 WAC 418.80
NDC 43376033060 Effective Date 01-08-2016 WAC 460.26 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224034060 |
Zohydro ER Oral Capsule 40 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
52.31 |
702.60 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, LLC |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
650.29 |
602.12 |
2014 |
431.40 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376034060 Effective Date 03-11-2015 WAC 431.40
NDC 43376034060 Effective Date 01-08-2016 WAC 474.11 |
| Rx0000182 |
Persion Pharmaceuticals LLC |
03/31/2020 |
65224035060 |
Zohydro ER Oral Capsule 50 mg 60 ct hydrocodone bitartrate |
01/01/2020 |
54.27 |
732.60 |
09/12/2034 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
1 |
04/30/2019 |
Pernix Therapeutics Holdings, LLC |
79600000 |
None |
The acquisition price reflects the total assets purchased out of bankruptcy - not limited to this single NDC. |
678.33 |
628.08 |
2014 |
450.00 |
None |
Persion Pharmaceuticals LLC acquired asset out of bankruptcy on April 30, 2019 from Pernix Therapeutics Holdings, Inc. All pricing history prior to April 30, 2019 is not Persion Pharmaceuticals LLC's history. For the sake of clarity, Persion Pharmaceuticals LLC is providing the five year history as required by the regulation and based upon pricing history as provided by MediSpan. Persion Pharmaceuticals LLC accepts no liability for pricing and pricing history prior to April 30, 2019.
This product was acquired along with several other products in a bankruptcy acquisition. The purchase amount for this specific product is not reported.
Please note the following pricing history as provided by MediSpan for the years prior to Persion acquiring the product.
NDC 43376035060 Effective Date 03-11-2015 WAC 450.00
NDC 43376035060 Effective Date 01-08-2016 WAC 494.55 |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121048900 |
DIPHENHYDRAMINE HCL ORAL SOLUTION USP 12.5 mg 5 mL 100 UDcups/case |
01/31/2020 |
26.90 |
298.53 |
None |
Non-innovator Multiple Source Drug |
2277 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121097800 |
DIPHENHYDRAMINE HCL ORAL SOLUTION USP 25 mg 10 mL 100 UDcups/case |
01/31/2020 |
28.23 |
313.29 |
None |
Non-innovator Multiple Source Drug |
2053 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121058105 |
HALOPERIDOL ORAL SOLUTION USP (CONCENTRATE), AF SF DF 10 mg 5 mL 100 UDcups/case |
01/31/2020 |
31.46 |
349.21 |
None |
Non-innovator Multiple Source Drug |
40332 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121481140 |
HYDROCODONE BITARTRATE & HOMATROPINE METHYLBROMIDE SYRUP CII 5 mg/1.5 mg 5 mL 40UDcups/case |
01/31/2020 |
27.49 |
305.15 |
None |
Non-innovator Multiple Source Drug |
3181 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121059500 |
SODIUM CITRATE and CITRIC ACID ORAL SOLUTION USP, AF SF DF 1500 mg/1002 mg 15 mL 100 UDcups/case |
01/31/2020 |
29.48 |
327.18 |
None |
Non-innovator Multiple Source Drug |
1591 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000135 |
Pharmaceutical Associates, Inc |
03/31/2020 |
00121119000 |
SODIUM CITRATE and CITRIC ACID ORAL SOLUTION USP, AF SF DF 3000 mg/2004 mg 30 mL 100 UDcups/case |
01/31/2020 |
31.99 |
355.04 |
None |
Non-innovator Multiple Source Drug |
2725 |
None |
PAI has incurred significant costs to remain compliant with updated USP requirements and FDA standards
Some examples of increased costs:
Costs to implement elemental impurities will total over $3 million
GDUFA fees have added almost $2 million per year in overhead costs
Licensing costs are rising exponentially |
None |
No change or improvement |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Drug was not acquired |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2020 |
57962014012 |
IMBRUVICA (ibrutinib); 140mg capsule; 120 ct |
01/02/2020 |
1276.26 |
18522.99 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
AbbVie Inc. acquired Pharmacyclics in May 2015 for approximately $21 billion. In 2013 the 120 count bottle of 140mg IMBRUVICA capsules was introduced to market at a WAC of $10,933.33. At the time of the 2015 acquisition, the 120 capsule bottle had a WAC of $12,225.10. |
| Rx0000237 |
Pharmacyclics an AbbVie Company |
03/31/2020 |
57962014009 |
IMBRUVICA (ibrutinib); 140mg capsule; 90 ct |
01/02/2020 |
957.19 |
13892.24 |
10/24/2034 |
Single Source Drug |
None |
1 |
Pharmacyclics pricing decisions regarding the WAC price of a medication are determined after careful consideration of a number of interdependent factors, including a) the clinical and economic value of the particular therapy b) the therapeutic category, its market dynamics, and competitor pricing; c) discounts provided to customers in both the commercial and government channels; d) patient support provided by Pharmacyclics to ensure patient access to life-saving and life-changing medications; e) overall research and development costs. |
None |
NA |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
AbbVie Inc. acquired Pharmacyclics in May 2015 for approximately $21 billion. In 2013 the 90 count bottle of 140mg IMBRUVICA capsules was introduced to market at a WAC of $8,200.00. At the time of the 2015 acquisition, the 90 capsule bottle had a WAC of $$9,168.83. |
| Rx0000225 |
PruGen, LLC |
03/31/2020 |
42546001660 |
BenzePro (benzoyl peroxide) 6% Foaming Cloths - 60 packets in 1 carton |
01/22/2020 |
32.74 |
500.47 |
None |
Single Source Drug |
13281 |
None |
Increase product, packaging and shipping costs from the contract manufacturer organization. |
None |
Increase in WAC product pricing due to increased overhead costs to supply the product to the virtual manufacturer. |
None |
08/01/2015 |
PruGen, LLC |
299 |
None |
None |
299.34 |
None |
2015 |
299.34 |
None |
No patent on this product |
| Rx0000225 |
PruGen, LLC |
03/31/2020 |
42546017516 |
SulfaCleanse 8/4 (sodium sulfacetamide & sulfur) suspension 8%-4% - 473ml |
01/20/2020 |
31.73 |
485.05 |
None |
Single Source Drug |
42751 |
None |
Increase product, packaging and shipping costs from the contract manufacturer organization. |
None |
Increase in WAC product pricing due to increased overhead costs to supply the product to the virtual manufacturer. |
None |
05/01/2011 |
PruGen, LLC |
100 |
None |
None |
99.72 |
None |
2011 |
99.72 |
None |
No Patent on this product |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050203 |
Emflaza 18 mg tablet, 30 |
01/01/2020 |
414.21 |
4965.92 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
3925.00 |
None |
2017 |
3925.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050303 |
Emflaza 30 mg tablet, 30 |
01/01/2020 |
690.38 |
8276.96 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
6542.00 |
None |
2017 |
6542.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050403 |
Emflaza 36 mg tablet, 30 |
01/01/2020 |
769.32 |
9223.33 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
7290.00 |
None |
2017 |
7290.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
42998050101 |
Emflaza 6 mg tablet, 100 |
01/01/2020 |
460.22 |
5517.55 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
4361.00 |
None |
2017 |
4361.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
03/31/2020 |
52856050522 |
Emflaza Oral suspension 22.75 mg/mL, 13ml |
01/01/2020 |
303.19 |
3634.93 |
None |
Single Source Drug |
None |
1 |
None |
1 |
PTC Therapeutics has determined that said price increase was necessary due to administrative costs that were associated with discontinued manufacturer inventory as well as improvement in packaging. |
None |
04/01/2017 |
Marathon |
75000000 |
None |
The acquisition price of Emflaza was comprised of: (i) $75.0 million in cash and (ii) 6,683,598 shares of PTC Therapeutics common stock, as well as (iii) contingent payments from PTC Therapeutics based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over its expected commercial life, up to $50.0 million, subject to the terms and conditions of the Asset Purchase Agreement. |
2873.00 |
None |
2017 |
2873.00 |
None |
None |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050203 |
Emflaza/ 18mg tabs/ 30 ct |
08/17/2020 |
451.90 |
5417.82 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
3925.00 |
0.00 |
2017 |
3925.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050522 |
Emflaza/ 22.75mg/mL susp/ 13ml in 30 ml bottle |
08/17/2020 |
330.78 |
3965.71 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
2873.00 |
0.00 |
2017 |
2873.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050303 |
Emflaza/ 30mg tabs/ 30 ct |
08/17/2020 |
753.20 |
9030.16 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
6542.00 |
0.00 |
2017 |
6542.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050403 |
Emflaza/ 36mg tabs/ 30 ct |
08/17/2020 |
839.32 |
10062.65 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
7290.00 |
0.00 |
2017 |
7290.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000236 |
PTC Therapeutics, Inc |
09/30/2020 |
52856050101 |
Emflaza/ 6mg tabs/ 100 ct |
08/17/2020 |
502.10 |
6019.65 |
02/01/2024 |
Single Source Drug |
None |
1 |
Extended internal Patient Services Group investment
Commercial investments and associated administrative costs
Increased manufacturing costs associated with direct materials cost, direct labor cost, and manufacturing overhead |
None |
None |
1 |
04/01/2017 |
Marathon Pharmaceuticals |
140000000 |
None |
PTC purchased product from Marathon prior to an official launch for a combination of stock and cash in 2017 |
4361.00 |
0.00 |
2017 |
4361.00 |
None |
Sales volumes are not provided publicly since launch. |
| Rx0000220 |
Puma Biotechnology, Inc. |
03/31/2020 |
70437024018 |
Nerlynx 40mg 180 tablets |
03/01/2020 |
1368.00 |
15191.00 |
12/31/2025 |
Single Source Drug |
17400 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Nerlynx was developed by Puma Biotechnology. |
| Rx0000220 |
Puma Biotechnology, Inc. |
09/30/2020 |
70437024018 |
Nerlynx 40mg 180 tablets |
07/31/2020 |
1504.00 |
16695.00 |
None |
Single Source Drug |
17400 |
None |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Nerlynx was developed by Puma |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075104 |
BUTRANS 10MCG/HOUR TDS 4S |
01/01/2020 |
22.05 |
462.98 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075804 |
BUTRANS 15 MCG/HOUR TDS 4S |
01/01/2020 |
31.80 |
667.84 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075204 |
BUTRANS 20MCG/HOUR TDS 4S |
01/01/2020 |
39.03 |
819.63 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075004 |
BUTRANS 5 MCG/HOUR TDS 4S |
01/01/2020 |
14.70 |
308.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011075704 |
BUTRANS 7.5 MCG/HOUR TDS 4S |
01/01/2020 |
20.58 |
432.10 |
None |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027660 |
HYSINGLA ER 100MG TABLETS 60S |
01/01/2020 |
132.37 |
2779.67 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027760 |
HYSINGLA ER 120MG TABLETS 60S |
01/01/2020 |
146.68 |
3080.37 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027160 |
HYSINGLA ER 20MG TABLETS 60S |
01/01/2020 |
28.34 |
595.07 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027260 |
HYSINGLA ER 30MG TABLETS 60S |
01/01/2020 |
41.36 |
868.59 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027360 |
HYSINGLA ER 40MG TABLETS 60S |
01/01/2020 |
55.72 |
1170.19 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027460 |
HYSINGLA ER 60MG TABLETS 60S |
01/01/2020 |
77.16 |
1620.34 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011027560 |
HYSINGLA ER 80MG TABLETS 60S |
01/01/2020 |
104.03 |
2184.61 |
12/21/2031 |
Single Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041010 |
OXYCONTIN 10MG TABLETS 100S |
01/01/2020 |
20.12 |
422.58 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041020 |
OXYCONTIN 10MG TABLETS HUD 20S |
01/01/2020 |
4.13 |
86.77 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041510 |
OXYCONTIN 15MG TABLETS 100S |
01/01/2020 |
29.62 |
622.11 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011041520 |
OXYCONTIN 15MG TABLETS HUD 20S |
01/01/2020 |
6.08 |
127.64 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011042010 |
OXYCONTIN 20MG TABLETS 100S |
01/01/2020 |
37.53 |
788.10 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011042020 |
OXYCONTIN 20MG TABLETS HUD 20S |
01/01/2020 |
7.70 |
161.66 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011043010 |
OXYCONTIN 30MG TABLETS 100S |
01/01/2020 |
52.19 |
1096.05 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011043020 |
OXYCONTIN 30MG TABLETS HUD 20S |
01/01/2020 |
10.71 |
224.88 |
03/29/2030 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011044010 |
OXYCONTIN 40MG TABLETS 100S |
01/01/2020 |
64.27 |
1349.70 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011044020 |
OXYCONTIN 40MG TABLETS HUD 20S |
01/01/2020 |
13.18 |
276.75 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011046010 |
OXYCONTIN 60MG TABLETS 100S |
01/01/2020 |
91.00 |
1910.96 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011046020 |
OXYCONTIN 60MG TABLETS HUD 20S |
01/01/2020 |
18.67 |
392.05 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011048010 |
OXYCONTIN 80MG TABLETS 100S |
01/01/2020 |
112.15 |
2355.18 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |
| Rx0000056 |
Purdue Pharma LP |
03/31/2020 |
59011048020 |
OXYCONTIN 80MG TABLETS HUD 20S |
01/01/2020 |
23.01 |
483.13 |
08/24/2027 |
Innovator Multiple Source Drug |
None |
1 |
None |
1 |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
"Note regarding patent dates: OxyContin patent expiration differs by product strength. Note regarding drug source type: OxyContin is an Innovator Multi-Source Drug as, although the patents have not yet expired, other companies have authorized generics to OxyContin on the market. General comments on Cost Increase Factors: As a private company, we do not publicly disclose a majority of this information. However, Purdue Pharma LP does continue to make significant investments into the research and development of new medicines to address unmet medical needs of patients. We are focusing our research and development efforts in various therapeutic areas, including oncology, non-pain CNS disorders (insomnia and ADHD), and non-opioid pain medications. Successful development of these therapies could produce both positive impacts for patients with unmet medical needs and the public health." |